Phase 1/2 study of CybroCell, the first dermal fibroblast cell product for treatment of degenerative disc disease

Trial Profile

Phase 1/2 study of CybroCell, the first dermal fibroblast cell product for treatment of degenerative disc disease

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 May 2018

At a glance

  • Drugs Human dermal fibroblasts-SpinalCyte (Primary)
  • Indications Intervertebral disc degeneration
  • Focus Adverse reactions
  • Most Recent Events

    • 17 May 2018 According to a SpinalCyte media release, the company announced that posters from this trial will be presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2018.
    • 12 Apr 2018 According to a SpinalCyte media release, company has filed an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) to expand this ongoing study.
    • 03 Apr 2018 According to a SpinalCyte media release, Preliminary six-month MRI data on 18 patients has been completed with an independent radiological expert providing MRI analysis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top